drugset / Trial / NCT00662792

Efficacy and Safety Comparison of Tiotropium Daily + Salmeterol Daily or Twice Daily Versus Tiotropium Daily in Patients With COPD

NCT00662792

Phase 3 Completed 147 enrolled Boehringer Ingelheim
RandomizedCrossoverDouble-blindTreatment

Summary

The primary objective of this trial is to establish superiority of the once-daily Tiotropium plus Salmeterol Inhalation Powder in daytime lung function response and non-inferiority in night-time lung function response over the comparator treatments inhaled in their established dose regimens when administered for 6-week periods to patients with chronic obstructive pulmonary disease (COPD). The main secondary objective is to evaluate the safety of the Tiotropium plus Salmeterol Inhalation Powder versus the comparator treatments.

Timeline

Start
2008-04-15
Primary completion
2009-07-22
Completion
2009-07-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Salmeterol Other / unclassified 50 ug Inhaled
Subject Tiotropium Other / unclassified 18 ug Inhaled
Subject Tiotropium/Salmeterol Unknown Inhaled